Finerenone Approved for a New Indication in China: 18% Reduction in Heart Failure Events and New Progress in HFpEF Treatment

Finerenone has been approved in China for adult heart failure patients with LVEF ≥40%, marking a significant advancement in HFpEF and HFmrEF treatment.

Top Stories

Latest Coverage

Spatial Biology: From 'Average Tumor' to 'Cell-Level Precision Therapy'
Tumor treatment is facing a profound paradigm shift.
FDA Officially Approves Saphnelo Auto-Injector: SLE Patients May Soon Say Goodbye to Long Infusion Sessions
On April 27, 2026 local time, AstraZeneca officially announced that Saphnelo (Anifrolumab subcutaneous injection) has...
Dual Oral Therapy, Chemotherapy-Free! EGFR-Mutant Lung Cancer Treatment May Enter a New Era
In recent years, precision treatment for lung cancer has continued to advance, and EGFR-mutant non-small cell lung ca...
7-Minute Immunotherapy Infusion! Atezolizumab Subcutaneous Injection Approved in China
In recent years, tumor immunotherapy has continued to develop rapidly, and PD-1/PD-L1 inhibitors have become importan...
Oral Dissolving Films: A New Dosage Form Transforming the Modern Medication Experience
For most people, taking medicine seems like a very ordinary part of life. However, not everyone can easily swallow pi...
Metformin Immediate-Release, Enteric-Coated, and Extended-Release Tablets: Do They Have the Same Blood Sugar-Lowering Effect?
Among the medications used to treat Type 2 Diabetes, Metformin has long been regarded as a “foundation therapy.”

In-Depth Analysis


This site uses Just the Docs, a documentation theme for Jekyll.